FDA stifles Merck’s cough drug gefapixant, asking for more dataThe FDA has issued a complete response letter (CRL) to Merck & Co’s gefapixant candidate for refractory chronic Share XFDA stifles Merck’s cough drug gefapixant, asking for more datahttps://pharmaphorum.com/news/fda-stifles-mercks-cough-drug-gefapixant-asking-for-more-data/
Bayer trumpets $1bn CRISPR deal with Mammoth BioBayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed Share XBayer trumpets $1bn CRISPR deal with Mammoth Biohttps://pharmaphorum.com/news/bayer-trumpets-crispr-deal-mammoth-bio/
Trial closes gap between Bayer’s Nubeqa and rivals in prostate cancerBayer’s Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track Share XTrial closes gap between Bayer’s Nubeqa and rivals in prostate cancerhttps://pharmaphorum.com/news/trial-narrows-gap-between-bayers-nubeqa-and-rivals-in-prostate-cancer/
Bayer, One Drop launch AI tool for heart disease preventionBayer’s two-year-old digital health collaboration with One Drop has borne its first fruit, an artificial intelligence-powered software module Share XBayer, One Drop launch AI tool for heart disease preventionhttps://pharmaphorum.com/news/bayer-one-drop-launch-ai-tool-for-heart-disease-prevention/
FDA clears Roche’s Susvimo implant for eye disease wet AMDRoche’s Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration Share XFDA clears Roche’s Susvimo implant for eye disease wet AMDhttps://pharmaphorum.com/news/fda-clears-roches-susvimo-implant-for-eye-disease-wet-amd/
Bayer teams up with Huma to apply AI to lung cancer diagnosisA research project between Bayer and digital health company Huma will use artificial intelligence to detect lung cancer Share XBayer teams up with Huma to apply AI to lung cancer diagnosishttps://pharmaphorum.com/news/bayer-teams-up-with-huma-to-apply-ai-to-lung-cancer-diagnosis/
Bayer’s eliapixant hits the right notes in PAGANINI cough studyBayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it Share XBayer’s eliapixant hits the right notes in PAGANINI cough studyhttps://pharmaphorum.com/news/bayers-eliapixant-hits-the-right-notes-in-paganini-cough-study/
Novartis says trials back Beovu safety in diabetic eye diseaseThere is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to Share XNovartis says trials back Beovu safety in diabetic eye diseasehttps://pharmaphorum.com/news/novartis-says-trials-back-beovu-safety-in-diabetic-eye-disease/
Bayer bolsters R&D platform with $2bn Vividion takeoverBayer headlined its second-quarter results this morning by unveiling a deal to buy Vividion Therapeutics, saying it will Share XBayer bolsters R&D platform with $2bn Vividion takeoverhttps://pharmaphorum.com/news/bayer-bolsters-rd-platform-with-2bn-vividion-takeover/
